Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.33 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24121974 | 0.78 | PDPK1 (0.46) | PDPK1YTHDC1YTHDF2ADORA2AADORA2B | |
| SCHEMBL11330441 | 0.77 | PDPK1 (0.42) | PDPK1YTHDC1YTHDF2ADORA2AADORA2B | |
| SCHEMBL10120030 | 0.75 | PI4KA (0.44) | PDPK1YTHDC1YTHDF2ADORA2AADORA2B | |
| SCHEMBL11337092 | 0.74 | TP53 (0.49) | PDPK1YTHDC1YTHDF2ADORA2AADORA2B | |
| SCHEMBL3237641 | 0.73 | KDM4E (0.42) | PDPK1YTHDC1YTHDF2ADORA2AADORA2B | |
| SCHEMBL21347895 | 0.70 | PDPK1 (0.43) | PDPK1YTHDC1YTHDF2ADORA2AADORA2B | |
| SCHEMBL21539447 | 0.70 | MTAP (0.39) | ADORA2A | |
| SCHEMBL11841747 | 0.69 | CCNB2 (0.51) | — | |
| SCHEMBL3241299 | 0.69 | KDM4E (0.36) | — | |
| SCHEMBL2808798 | 0.68 | CCNB2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | PDPK1 4458/4885YTHDC1 4269/4885YTHDF2 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.